Article
Oncology
Morgan Homan, Govind Warrier, Christopher D. Lao, Sarah Yentz, Shawna Kraft, Leslie A. Fecher
Summary: This study describes the treatment-related toxicities of adjuvant dabrafenib and trametinib combination therapy for patients with resected melanoma and finds that the majority of patients experience treatment-limiting toxicities. Therefore, close monitoring of patients is necessary during treatment.
FRONTIERS IN ONCOLOGY
(2022)
Article
Dermatology
Bongyong Lee, Anupama Sahoo, Junko Sawada, John Marchica, Sanjay Sahoo, Fabiana I. A. L. Layng, Darren Finlay, Joseph Mazar, Piyush Joshi, Masanobu Komatsu, Kristiina Vuori, Petrus R. de Jong, Animesh Ray, Ranjan J. Perera
Summary: miR-211 promotes aggressive growth of BRAF(V600E)-mutant melanoma xenografts by activating ERK5 signaling pathway, leading to increased resistance of melanoma cells to BRAF and MAPK/ERK kinase inhibitors. This indicates a potential mechanism for developing drug-resistant tumors and a target for overcoming resistance.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2021)
Article
Oncology
Martin Salzmann, Alexander Wald, Henner Stege, Carmen Loquai, Lisa Zimmer, Kinan M. Hayani, Lucie Heinzerling, Ralf Gutzmer, Alexander H. Enk, Jessica C. Hassel
Summary: Patients with metastasized melanoma can be treated with different combinations of targeted therapy tablets. A study conducted at six German cancer centers found that switching to a different combination can be a feasible and rational approach when the initial combination is not tolerated well. The new combination was overall better tolerated and had similar efficacy, but new side effects may occur.
Article
Pharmacology & Pharmacy
Aml Mekkawy, Youssef W. Naguib, Suhaila O. Alhaj-Suliman, Emad Wafa, Kareem Ebeid, Timothy Acri, Aliasger K. Salem
Summary: The study explores the efficacy of a combination therapy of PTX and PD98059 in enhancing cytotoxicity against melanoma cells expressing the BRAF mutation. The use of PD98059-loaded NPs showed superior cellular uptake and cytotoxicity compared to soluble PD98059, suggesting a potential therapeutic approach for improving survival outcomes in patients with metastatic melanoma.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2021)
Article
Oncology
Shuyang S. Qin, Booyeon J. Han, Alyssa Williams, Katherine M. Jackson, Rachel Jewell, Alexander C. Chacon, Edith M. Lord, David C. Linehan, Minsoo Kim, Alexandre Reuben, Scott A. Gerber, Peter A. Prieto
Summary: Metastatic melanoma patients may present with multiple, genetically different simultaneous metastases that respond differently to systemic therapy. A novel murine model has shown that tumors in the same mouse can independently regulate the expression of immune checkpoint molecules PD-1 and PD-L1, providing insight into intertumoral heterogeneity and lesion-specific therapeutic responses. Further investigations into this model may guide therapeutic selection in challenging patient populations.
Article
Oncology
Hannah M. Knochelmann, Michael Brandon Ware, Aditya Rali, Susanne Linderman, Jessica G. Shantha, David H. Lawson, Melinda Yushak, Robert Swerlick, Chrystal M. Paulos, Steven Yeh, Ragini Kudchadkar
Summary: Autoimmune toxicities following treatment with BRAF/MEK inhibitors are not well-understood. This article describes a case of a patient with recurrent/metastatic melanoma who experienced delayed autoimmune-like reactions after treatment with BRAF/MEK inhibitors, suggesting a possible role for Th/Tc17 activation in their pathogenesis.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Amanda McDaniel, Bruce Freimark, Cebrina Navarro, Kristin Von Rothstein, Dacia Gonzalez, Keith Linder, Richard Nuccitelli
Summary: Nano-Pulse Stimulation (NPS) Therapy is a new bioelectric modality that uses ultrashort pulses of electric energy to trigger regulated cell death in tissues. Compared to cryoablation, NPS is more effective in clearing melanoma lesions with minimal skin damage.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Ahmed F. Essa, Seham S. El-Hawary, Sherif E. Emam, Tahia M. Kubacy, Ezz El-Din A. M. El-Khrisy, Inas Y. Younis, Abdelsamed I. Elshamy
Summary: Three undescribed diterpenes were isolated from Euphorbia mauritanica, and their structures and stereochemistry were determined. Some of these compounds showed significant inhibitory effects against melanoma cells, and their mechanisms of action were elucidated through molecular docking. In-silico pharmacokinetics predictions indicated the potential oral bioavailability and drug-like properties of these active compounds.
Article
Dermatology
Soraya Naimy, Michael Bzorek, Jens Ole Eriksen, Beatrice Dyring-Andersen, Lise Mette Rahbek Gjerdrum
Summary: This study examined the expression patterns of BRAF(V600E) in primary treatment-naive melanomas. The results showed that BRAF(V600E) is homogeneously present throughout the whole tumor and is associated with nonrecurrent disease and better survival. Additionally, it was found that BRAF(V600E) mutation does not result in higher transcriptional levels.
Article
Medicine, General & Internal
Gianluca Nazzaro, Emanuela Passoni, Fabio Pozzessere, Carlo Alberto Maronese, Angelo Valerio Marzano
Summary: This study compared melanomas diagnosed at the Dermatology Unit of Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan, Italy, from 2006 to 2020 and between two specific biennia, i.e., 2006-2007 and 2019-2020. The results showed a significant increase in the proportions of in situ melanoma and small-diameter melanoma (less than 6 mm) across the studied period.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Environmental Sciences
Aliciane de Almeida Roque, Jessica Zablocki da Luz, Michelle Thays Khun Santurio, Francisco Filipak Neto, Ciro Alberto de Oliveira Ribeiro
Summary: In this study, the effects of pesticides widely used in Brazil and their main metabolites on the malignancy of melanoma cells were investigated. The results showed that these chemicals modulate important parameters of tumor progression, such as gene expression related to tumor aggressiveness and multidrug resistance. These findings raise concerns about the increasing trend in pesticide use in Brazil and its potential negative impact on melanoma progression.
ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
(2023)
Article
Oncology
Michael G. White, Robert Szczepaniak Sloane, Russell G. Witt, Alexandre Reuben, Pierre Olivier Gaudreau, Miles C. Andrews, Ningping Feng, Sarah Johnson, Caleb A. Class, Christopher Bristow, Khalida Wani, Courtney Hudgens, Luigi Nezi, Teresa Manzo, Mariana Pettaccia De Macedo, Jianhua Hu, Richard Davis, Hong Jiang, Peter Prieto, Elizabeth Burton, Patrick Hwu, Hussein Tawbi, Jeffrey Gershenwald, Alexander J. Lazar, Michael T. Tetzlaff, Willem Overwijk, Scott E. Woodman, Zachary A. Cooper, Joseph R. Marszalek, Michael A. Davies, Timothy P. Heffernan, Jennifer A. Wargo
Summary: Targeted and immunotherapy combinations have revolutionized the treatment of advanced melanoma, but durable responses are limited. Multi-drug regimens may offer more durable disease control but come with increased toxicity.
Article
Biochemistry & Molecular Biology
Jana Jandova, Sophia L. Park, Mandi J. Corenblum, Lalitha Madhavan, Jeremy A. Snell, Liliana Rounds, Georg T. Wondrak
Summary: The study suggests that the clinical antimalarial drug mefloquine may be an effective candidate for drug repurposing to eliminate malignant melanoma cells, even when metastasized to the brain and resistant to BRAF kinase inhibitors.
MOLECULAR CARCINOGENESIS
(2022)
Article
Dermatology
Jana Jandova, Georg T. Wondrak
Summary: This study reveals that BRAFi treatment exacerbates the upregulation of epithelial-to-mesenchymal transition (EMT) genes in BRAFV600E/NRASQ61K cells, promoting invasiveness and metastasis. These findings have potential implications for the treatment of NRAS-driven BRAFi-resistant tumors.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Article
Oncology
Vincent Sibaud, Lilian Baric, Alain Cantagrel, Mario Di Palma, Stephane Ederhy, Michel Paques, Gabriel Perlemuter
Summary: Recent major therapeutic advances have been made in the treatment of metastatic melanoma, particularly with the development of targeted therapies targeting BRAF and MEK mutations. The combination therapies approved in various trials have different toxicities compared to monotherapies, leading to new challenges for physicians in managing these adverse events.
BULLETIN DU CANCER
(2021)
